Xeris Biopharma Holdings, Inc. Form 8-K Summary
Business context and reporting period
On November 10, 2021, Xeris Biopharma Holdings, Inc. furnished a Form 8-K reporting that it issued a press release regarding results of operations and business highlights for the three and nine months ended September 30, 2021. The filing identifies the company as an emerging growth company and its common stock as traded on The Nasdaq Global Select Market under the symbol XERS.
Financial results and key metrics
The filing text provided does not include the accompanying Exhibit 99.1 press release or specific figures for revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. Accordingly, no clear values or period-over-period comparisons are available from the provided text.
Material changes versus the prior comparable period
The filing states that the press release contains results of operations and business highlights, but the provided filing text does not describe any material changes versus the prior comparable periods.
Guidance, outlook, risks, contingencies, and unusual items
No guidance, outlook, management commentary, risks, contingencies, or unusual items are included in the provided filing text. The Form 8-K states that the information, including Exhibit 99.1, is furnished rather than filed for purposes of Section 18 of the Exchange Act, except where expressly incorporated by reference.
Important facts to verify
- Obtain and review Exhibit 99.1 for the detailed third-quarter and nine-month 2021 financial results.
- Verify revenue, net loss or profit, cash flow, cash balance, debt, liquidity, and margins for the periods ended September 30, 2021.
- Review management’s business highlights, guidance, outlook, and discussion of risks or unusual items in the press release.
- Confirm any reported changes from the comparable 2020 periods and any non-GAAP measures or reconciliations.